Growth inhibition and chemosensitivity of poorly differentiated human thyroid cancer cell line (NPA) transfected with p53 gene

Head Neck. 2001 Mar;23(3):223-9. doi: 10.1002/1097-0347(200103)23:3<223::aid-hed1022>3.0.co;2-y.

Abstract

Background: We investigated whether retroviral p53 transfection could enhance growth inhibition and chemosensitivity in a p53 mutant papillary thyroid cancer cell line (NPA).

Methods: NPA cells were transfected with either LXSN/p53 or mock infection in the presence of Adriamycin. Gene expression was confirmed by western blotting. Nude mice were injected subcutaneously with NPA cells after transfection with either LXSN/p53 or mock infection on opposite sides, and the tumor growth was compared.

Results: There was a dose-dependent inhibition of tumor growth with LXSN/p53 transfection. Tumor growth was inhibited more by p53 gene transfection relative to mock transfection in the presence of Adriamycin.

Conclusion: These treatment modalities could be beneficial in the treatment of p53 mutant positive thyroid cancers.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Division / drug effects
  • Dose-Response Relationship, Drug
  • Doxorubicin / pharmacology*
  • Gene Expression Regulation
  • Gene Transfer Techniques
  • Genes, p53 / genetics*
  • Genetic Therapy / methods
  • Humans
  • Immunohistochemistry
  • Mice
  • Mice, Nude
  • Microbial Sensitivity Tests
  • Probability
  • Sensitivity and Specificity
  • Thyroid Neoplasms / genetics
  • Thyroid Neoplasms / pathology*
  • Thyroid Neoplasms / therapy*
  • Tumor Cells, Cultured

Substances

  • Doxorubicin